ICOTYDE (icotrokinra)
Product · Pharmaceutical / drug by Johnson & Johnson
A first-in-class targeted oral peptide therapy for plaque psoriasis and psoriatic arthritis.
ICOTYDE is a first-of-its-kind targeted oral peptide therapy developed by Johnson & Johnson Innovative Medicine for moderate to severe plaque psoriasis and psoriatic arthritis. As a once-daily pill, it offers a significant advancement over traditional injectable therapies by targeting the IL-23R pathway with precision. Clinical studies have demonstrated that 58% of treated patients achieved an ACR20 response at Week 16, showing meaningful improvements in both joint and skin symptoms. The therapy is designed for biologic-naive patients and maintains a favorable safety profile. It was recognized
- Languages
- English
- ACR20 response at Week 16
- 58%
- Dosing frequency
- Once-daily
- Target pathway
- IL-23R
Overview
ICOTYDE is a first-of-its-kind targeted oral peptide therapy developed by Johnson & Johnson Innovative Medicine for moderate to severe plaque psoriasis and psoriatic arthritis. As a once-daily pill, it offers a significant advancement over traditional injectable therapies by targeting the IL-23R pathway with precision. Clinical studies have demonstrated that 58% of treated patients achieved an ACR20 response at Week 16, showing meaningful improvements in both joint and skin symptoms. The therapy is designed for biologic-naive patients and maintains a favorable safety profile. It was recognized as one of Time's Best Inventions of 2026 for its originality and impact on patient care.
Clinical Applications
- Targeted oral peptide: The medication is a first-in-class IL-23R targeted oral peptide therapy.
- Plaque psoriasis treatment: It is indicated for adult patients with moderate to severe plaque psoriasis.
- Psoriatic arthritis efficacy: Clinical data shows significant improvement in psoriatic arthritis disease activity among biologic-naive patients.
Specifications
- ACR20 response at Week 16
- 58%
- Dosing frequency
- Once-daily
- Target pathway
- IL-23R
Added by AntSpace from public sources (jnj.com).